Mind Medicine Inc Ordinary Shares MNMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MNMD is a good fit for your portfolio.
News
-
MindMed to Participate at May Investor Conferences
-
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
-
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
-
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
-
MindMed to Present at Upcoming May Medical Conferences
-
MindMed to Present at Upcoming April Medical Conferences
-
MindMed Announces Voluntary Delisting from Cboe Canada
Trading Information
- Previous Close Price
- $9.12
- Day Range
- $8.78–9.39
- 52-Week Range
- $2.41–12.22
- Bid/Ask
- $9.16 / $9.40
- Market Cap
- $665.54 Mil
- Volume/Avg
- 874 / 2.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.mindmed.co
Comparables
Valuation
|
Metric
|
MNMD
|
CRNX
|
BLU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.06 | 6.44 | 5.83 |
Price/Sales | — | 736.42 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MNMD
CRNX
BLU
Financial Strength
|
Metric
|
MNMD
|
CRNX
|
BLU
|
|---|---|---|---|
Quick Ratio | 3.09 | 17.59 | 32.13 |
Current Ratio | 3.22 | 17.72 | 33.42 |
Interest Coverage | — | — | −1,125.80 |
Quick Ratio
MNMD
CRNX
BLU
Profitability
|
Metric
|
MNMD
|
CRNX
|
BLU
|
|---|---|---|---|
Return on Assets (Normalized) | −44.54% | −38.81% | −21.75% |
Return on Equity (Normalized) | −61.63% | −44.79% | −26.24% |
Return on Invested Capital (Normalized) | −61.14% | −45.62% | −24.47% |
Return on Assets
MNMD
CRNX
BLU
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bldqnvtrj | Dgv | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bzdbcsl | Nxxbylt | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xllgzhrj | Smvfp | $105.3 Bil | |
MRNA
| Moderna Inc | Pgtcvjds | Vbqc | $47.0 Bil | |
ARGX
| argenx SE ADR | Chyfvcsb | Kyrrf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qtxdxmpqt | Mrt | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sqmhptd | Kgzlfc | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wdxkmjbg | Zpcrv | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rwnkzmpcgm | Tswccgn | $12.7 Bil | |
INCY
| Incyte Corp | Xprwcnb | Dndfc | $12.0 Bil |